JP2010529153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529153A5 JP2010529153A5 JP2010511526A JP2010511526A JP2010529153A5 JP 2010529153 A5 JP2010529153 A5 JP 2010529153A5 JP 2010511526 A JP2010511526 A JP 2010511526A JP 2010511526 A JP2010511526 A JP 2010511526A JP 2010529153 A5 JP2010529153 A5 JP 2010529153A5
- Authority
- JP
- Japan
- Prior art keywords
- androst
- cyano
- methylene
- methyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 10
- 229940011871 estrogen Drugs 0.000 claims 7
- 239000000262 estrogen Substances 0.000 claims 7
- 206010027304 Menopausal symptoms Diseases 0.000 claims 6
- 229940127234 oral contraceptive Drugs 0.000 claims 2
- 239000003539 oral contraceptive agent Substances 0.000 claims 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims 1
- 102000009151 Luteinizing Hormone Human genes 0.000 claims 1
- 108010073521 Luteinizing Hormone Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229940083712 aldosterone antagonist Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940035811 conjugated estrogen Drugs 0.000 claims 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- 229930182833 estradiol Natural products 0.000 claims 1
- 229960004766 estradiol valerate Drugs 0.000 claims 1
- 229960002568 ethinylestradiol Drugs 0.000 claims 1
- 229940040129 luteinizing hormone Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004364 Benzylated hydrocarbon Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007027637A DE102007027637A1 (de) | 2007-06-12 | 2007-06-12 | 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| PCT/EP2008/004429 WO2008151746A2 (de) | 2007-06-12 | 2008-06-04 | 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVAT, DESSEN VERWENDUNG UND DAS DERIVAT ENTHALTENDE ARZNEIMITTEL |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010529153A JP2010529153A (ja) | 2010-08-26 |
| JP2010529153A5 true JP2010529153A5 (enExample) | 2013-08-15 |
Family
ID=39986163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010511526A Pending JP2010529153A (ja) | 2007-06-12 | 2008-06-04 | １７β−シアノ−１９−ノル−アンドロスタ−４−エン誘導体、その使用、及び当該誘導体を含む医薬 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8207150B2 (enExample) |
| EP (1) | EP2170925B1 (enExample) |
| JP (1) | JP2010529153A (enExample) |
| KR (1) | KR20100028554A (enExample) |
| CN (1) | CN101679478A (enExample) |
| AR (1) | AR066971A1 (enExample) |
| AU (1) | AU2008261278A1 (enExample) |
| BR (1) | BRPI0813937A2 (enExample) |
| CA (1) | CA2690959A1 (enExample) |
| DE (1) | DE102007027637A1 (enExample) |
| ES (1) | ES2397996T3 (enExample) |
| IL (1) | IL202359A0 (enExample) |
| MX (1) | MX2009013629A (enExample) |
| PA (1) | PA8784401A1 (enExample) |
| PE (1) | PE20090822A1 (enExample) |
| RU (1) | RU2010100331A (enExample) |
| TW (1) | TW200909444A (enExample) |
| UY (1) | UY31146A1 (enExample) |
| WO (1) | WO2008151746A2 (enExample) |
| ZA (1) | ZA201000187B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007027635A1 (de) * | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| DE102007027637A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| WO2010066355A1 (de) * | 2008-12-12 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG |
| WO2012059594A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Pharma Aktiengesellschaft | Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity |
| CN104530165A (zh) * | 2014-12-10 | 2015-04-22 | 浙江仙琚制药股份有限公司 | 制备4,9-双烯物的方法 |
| CN105085596A (zh) * | 2015-08-18 | 2015-11-25 | 湖北竹溪人福药业有限责任公司 | 一种羧酸黄体酮的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3043833A (en) * | 1961-07-14 | 1962-07-10 | Ormonoterapia Richter Spa | 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof |
| DE1183500B (de) | 1962-10-12 | 1964-12-17 | Schering Ag | Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe |
| US3579509A (en) * | 1965-06-21 | 1971-05-18 | Smith Kline French Lab | Process and 6-beta-substituted ethyl intermediates for preparing 6,6-ethylene-3-keto-delta**4 steroids |
| GB1089945A (en) * | 1965-09-23 | 1967-11-08 | British Drug Houses Ltd | Steroidal-6-spirocyclopropyl-4-en-3-ones |
| CH538462A (de) * | 1970-10-07 | 1973-06-30 | Ciba Geigy Ag | Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen |
| US3705179A (en) | 1971-03-15 | 1972-12-05 | American Home Prod | Antiandrogenic steroids |
| FR2139708B1 (enExample) | 1971-06-01 | 1974-08-23 | Roussel Uclaf | |
| BE795241A (fr) | 1972-02-11 | 1973-08-09 | Schering Ag | 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation |
| DE2456068A1 (de) | 1974-11-23 | 1976-08-12 | Schering Ag | Verfahren zur herstellung von oestren3,17-dion-derivaten |
| NL7701384A (nl) | 1977-02-10 | 1978-08-14 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks. |
| DE2922500A1 (de) | 1979-05-31 | 1980-12-04 | Schering Ag | 6 beta .7 beta |
| US4252800A (en) * | 1979-10-05 | 1981-02-24 | United States Of America | 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals |
| US4512986A (en) * | 1983-07-26 | 1985-04-23 | Research Triangle Institute | Progrestationally active steroids |
| US4544554A (en) * | 1983-09-26 | 1985-10-01 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| DE3402329A1 (de) | 1984-01-20 | 1985-08-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| DD281393A5 (de) * | 1984-12-10 | 1990-08-08 | Jenapharm Veb | Verfahren zur herstellung von steroid-c-17 beta-carbonitrilen |
| DD281394A5 (de) * | 1984-12-10 | 1990-08-08 | Jenapharm Veb | Verfahren zur herstellung von steroid-c-17 alpha-carbonitrilen |
| DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| EP0785211A1 (en) * | 1996-01-22 | 1997-07-23 | Laboratoire Theramex | New substituted 19-nor-pregnane derivatives |
| DE19651000A1 (de) | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
| DE102004063864A1 (de) | 2004-12-30 | 2006-07-13 | Schering Ag | 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
| DE102007027637A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
-
2007
- 2007-06-12 DE DE102007027637A patent/DE102007027637A1/de not_active Withdrawn
-
2008
- 2008-06-04 WO PCT/EP2008/004429 patent/WO2008151746A2/de not_active Ceased
- 2008-06-04 ES ES08758990T patent/ES2397996T3/es active Active
- 2008-06-04 RU RU2010100331/04A patent/RU2010100331A/ru not_active Application Discontinuation
- 2008-06-04 JP JP2010511526A patent/JP2010529153A/ja active Pending
- 2008-06-04 CA CA2690959A patent/CA2690959A1/en not_active Abandoned
- 2008-06-04 CN CN200880020020A patent/CN101679478A/zh active Pending
- 2008-06-04 AU AU2008261278A patent/AU2008261278A1/en not_active Abandoned
- 2008-06-04 KR KR1020097025930A patent/KR20100028554A/ko not_active Withdrawn
- 2008-06-04 BR BRPI0813937-7A2A patent/BRPI0813937A2/pt not_active Application Discontinuation
- 2008-06-04 MX MX2009013629A patent/MX2009013629A/es not_active Application Discontinuation
- 2008-06-04 EP EP08758990A patent/EP2170925B1/de not_active Not-in-force
- 2008-06-11 UY UY31146A patent/UY31146A1/es not_active Application Discontinuation
- 2008-06-11 US US12/137,111 patent/US8207150B2/en not_active Expired - Fee Related
- 2008-06-11 PE PE2008000994A patent/PE20090822A1/es not_active Application Discontinuation
- 2008-06-11 TW TW097121802A patent/TW200909444A/zh unknown
- 2008-06-11 PA PA20088784401A patent/PA8784401A1/es unknown
- 2008-06-12 AR ARP080102499A patent/AR066971A1/es unknown
-
2009
- 2009-11-26 IL IL202359A patent/IL202359A0/en unknown
-
2010
- 2010-01-11 ZA ZA2010/00187A patent/ZA201000187B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010529153A5 (enExample) | ||
| JP5871807B2 (ja) | ネストロン（ｎｅｓｔｏｒｏｎｅ（登録商標））を使用する神経保護およびミエリン修復 | |
| ES2558030T3 (es) | Método anticonceptivo oral multifásico de ciclo prolongado | |
| CN101626760A (zh) | 利用递增剂量长周期给药方案进行激素治疗的方法 | |
| PE20070208A1 (es) | Anticoncepcion oral con trimegestona | |
| RU2009148278A (ru) | Применение эстриола в низкой дозе | |
| AR057060A1 (es) | Composiciones de tanaproget que contienen etinil estradiol | |
| UY30461A1 (es) | Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas. | |
| CN1652798A (zh) | 连续抑制硫酸酯酶的孕激素的激素替代疗法 | |
| Zhu et al. | Antidepressant-like effects of sodium butyrate in combination with estrogen in rat forced swimming test: Involvement of 5-HT1A receptors | |
| NO327588B1 (no) | Farmasoytisk sammensetning og preparat omfattende etinylostradiol og drospirenon for anvendelse som antikonsepsjonsmiddel | |
| PE20070188A1 (es) | Formulaciones de estrogenos conjugados y bazedoxifeno | |
| RU2010100331A (ru) | ПРОИЗВОДНОЕ 17β-ЦИАНО-19-НОР-АНДРОСТ-4-ЕНА, ЕГО ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА, СОДЕРЖАЩИЕ УКАЗАННОЕ ПРОИЗВОДНОЕ | |
| HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
| DE102008057230A1 (de) | Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin | |
| JP2013047269A5 (enExample) | ||
| AR044450A1 (es) | Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas | |
| CN101237836A (zh) | 用于避孕的药物控释装置的新方案 | |
| HRP20080394T3 (hr) | Peroralna dozna forma u krutom stanju namjenjena kontracepciji, koja sadrži dienogest i etinilestradiol | |
| Baird | Clinical uses of antiprogestogens | |
| CY1110348T1 (el) | Φαρμακευτικη μορφη για ληψη απο του στοματος με dienogest και αιθινυλ-οιστραδιολη για αντισυλληψη | |
| MD2850F1 (en) | Method of inducing the medicamental abortion | |
| Iosif et al. | Effects of tamoxifen and estradiol on estrogen binding sites in the urogenital tract: an experimental study in the rabbit | |
| Jasuja et al. | 95 DIHYDROTESTOSTERONE-INDUCED CONFORMATIONAL PERTURBATIONS IN ANDROGEN RECEPTOR: KINETIC AND THERMODYNAMIC INSIGHTS. | |
| TH101223A (th) | ส่วนประกอบทางเภสัชกรรมของระบบใหม่ที่ใช้ในการปลดปล่อยสารสเตียรอยด์ทางช่องคลอด |